Title: Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma
Authors: Rasmussen, Rikke D * ×
Gajjar, Madhavsai K *
Jensen, Kamilla E
Hamerlik, Petra #
Issue Date: May-2016
Publisher: Elsevier Science
Series Title: Molecular Oncology vol:10 issue:5
Article number: S1574-7891(16)00002-8
Abstract: Recent clinical trials have demonstrated that targeting chromatin remodeling factors is as a promising strategy for the treatment of glioblastoma (GBM). We and others have shown constitutive activation of DNA damage response (DDR) pathways in gliomas and suggested that targeting the DDR may improve the currently grim prognosis for patients. Based on our previous findings that inhibition of poly(ADP-ribose) polymerase (PARP) increases radio-sensitivity of the notoriously radio-resistant GBM cells, we hypothesized that epigenetic down-regulation of the DDR responses and induction of oxidative stress via HDAC inhibition would contribute to more efficient targeting of this deadly disease. Our data show that SAHA, an HDAC class I + II inhibitor, in combination with olaparib (PARP inhibitor): i) enhanced inhibition of GBM cell survival, ii) induced apoptosis, and iii) impaired cell cycle progression. These results provide a pre-clinical rationale for combined administration of SAHA and olaparib, which are already individually in clinical trials.
ISSN: 1574-7891
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Non-KU Leuven Association publications
* (joint) first author
× corresponding author
# (joint) last author

Files in This Item:
File Description Status SizeFormat
Enhanced efficacy of combined HDAC and PARP targeting in glioblastoma.pdf Accepted 1956KbAdobe PDFView/Open Request a copy

These files are only available to some KU Leuven Association staff members


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science